Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA PharmaceuticalsMEX:ACAD 75 3-Year Book Growth Rate is 42.90% as of Jun. 2026, which is 377% above its 10-year median of 9.00. GuruFocus rates MEX:ACAD with a GF Score™ of 75/100 and a GF Value™ of MXN355.23 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,123 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 92.25% on this metric.
During the past 12 months, ACADIA Pharmaceuticals's average Book Value per Share Growth Rate was 55.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 42.90% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 11.80% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 5.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of ACADIA Pharmaceuticals was 91.30% per year. The lowest was -48.00% per year. And the median was 9.00% per year.
ACADIA Pharmaceuticals (MEX:ACAD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
ACADIA Pharmaceuticals 3-Year Book Growth Rate Related Terms
MEX:ACAD vs PBLS, DYN, EWTX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's 3-Year Book Growth Rate falls into.
ACADIA Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 42.90% mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a 3-Year Book Growth Rate of 42.90% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for ACADIA Pharmaceuticals and its competitors. This is 377% above median its historical median of 9.00. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #87 out of 1123 companies in the Biotechnology industry, placing it in the top 7.7%.
Is ACADIA Pharmaceuticals' 3-Year Book Growth Rate too high?
ACADIA Pharmaceuticals' current 3-Year Book Growth Rate of 42.90% is 377% above median its 10-year median of 9.00. Based on the distribution chart, ACADIA Pharmaceuticals ranks #87 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' 3-Year Book Growth Rate compare to PBLS and DYN?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #87 out of 1123 companies for 3-Year Book Growth Rate. This places ACADIA Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current 3-Year Book Growth Rate is 42.90%, which is 377% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN355.23, compared to a current price of MXN499.00 — trading 40.5% above its estimated fair value. The current 3-Year Book Growth Rate is 42.90%, which is 377% above median its 10-year median of 9.00. ACADIA Pharmaceuticals' overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current 3-Year Book Growth Rate is 42.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN499.00 is trading 40.5% above its estimated GF Value™ of MXN355.23.
GuruFocus considers ACADIA Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:ACAD:
3-Year Book Growth Rate: 42.90% (377% above median its 10-year median of 9.00)
GF Value™: MXN355.23 vs. price of MXN499.00 (40.5% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
75GF Score
Get the complete analysis for MEX:ACAD
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
